These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36546902)

  • 1. Heparin-Independent and Heparin-Dependent Anti-CXCL4 Antibodies Have a Reciprocal Expression in a Systemic Sclerosis Patients' Cohort.
    Palazzo R; Stefanantoni K; Cadar M; Butera A; Riccieri V; Lande R; Frasca L
    Antibodies (Basel); 2022 Dec; 11(4):. PubMed ID: 36546902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-CXCL4 Antibody Reactivity Is Present in Systemic Sclerosis (SSc) and Correlates with the SSc Type I Interferon Signature.
    Lande R; Mennella A; Palazzo R; Pietraforte I; Stefanantoni K; Iannace N; Butera A; Boirivant M; Pica R; Conrad C; Chizzolini C; Riccieri V; Frasca L
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32707718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Autoantibody Specificities in Systemic Sclerosis and Very Early Systemic Sclerosis.
    Lande R; Palazzo R; Mennella A; Pietraforte I; Cadar M; Stefanantoni K; Conrad C; Riccieri V; Frasca L
    Antibodies (Basel); 2021 Mar; 10(2):. PubMed ID: 33800661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution to the peripheral vasculopathy and endothelial cell dysfunction by CXCL4 in Systemic Sclerosis.
    Jiang Z; Chen C; Yang S; He H; Zhu X; Liang M
    J Dermatol Sci; 2021 Oct; 104(1):63-73. PubMed ID: 34556381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CXCL4-RNA Complexes Circulate in Systemic Sclerosis and Amplify Inflammatory/Pro-Fibrotic Responses by Myeloid Dendritic Cells.
    Pietraforte I; Butera A; Gaddini L; Mennella A; Palazzo R; Campanile D; Stefanantoni K; Riccieri V; Lande R; Frasca L
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCL4 assembles DNA into liquid crystalline complexes to amplify TLR9-mediated interferon-α production in systemic sclerosis.
    Lande R; Lee EY; Palazzo R; Marinari B; Pietraforte I; Santos GS; Mattenberger Y; Spadaro F; Stefanantoni K; Iannace N; Dufour AM; Falchi M; Bianco M; Botti E; Bianchi L; Alvarez M; Riccieri V; Truchetet ME; C L Wong G; Chizzolini C; Frasca L
    Nat Commun; 2019 May; 10(1):1731. PubMed ID: 31043596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease.
    Volkmann ER; Tashkin DP; Roth MD; Clements PJ; Khanna D; Furst DE; Mayes M; Charles J; Tseng CH; Elashoff RM; Assassi S
    Arthritis Res Ther; 2016 Dec; 18(1):305. PubMed ID: 28038680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia and TLR9 activation drive CXCL4 production in systemic sclerosis plasmacytoid dendritic cells via mtROS and HIF-2α.
    Ottria A; Zimmermann M; Paardekooper LM; Carvalheiro T; Vazirpanah N; Silva-Cardoso S; Affandi AJ; Chouri E; V D Kroef M; Tieland RG; Bekker CPJ; Wichers CGK; Rossato M; Mocholi-Gimeno E; Tekstra J; Ton E; van Laar JM; Cossu M; Beretta L; Garcia Perez S; Pandit A; Bonte-Mineur F; Reedquist KA; van den Bogaart G; Radstake TRDJ; Marut W
    Rheumatology (Oxford); 2022 May; 61(6):2682-2693. PubMed ID: 34559222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of cytokines CXCL4, CXCL8 and GDF15 as biomarkers in systemic sclerosis.
    Oller-Rodríguez JE; Vicens Bernabeu E; Gonzalez-Mazarío R; Grau García E; Ortiz Sanjuan FM; Román Ivorra JA
    Med Clin (Barc); 2022 Oct; 159(8):359-365. PubMed ID: 35039167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low heme oxygenase-1 levels in patients with systemic sclerosis are associated with an altered Toll-like receptor response: another role for CXCL4?
    van Bon L; Cossu M; Scharstuhl A; Pennings BW; Vonk MC; Vreman HJ; Lafyatis RL; van den Berg W; Wagener FA; Radstake TR
    Rheumatology (Oxford); 2016 Nov; 55(11):2066-2073. PubMed ID: 27411481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Target organ expression and biomarker characterization of chemokine CCL21 in systemic sclerosis associated pulmonary arterial hypertension.
    Didriksen H; Molberg Ø; Mehta A; Jordan S; Palchevskiy V; Fretheim H; Gude E; Ueland T; Brunborg C; Garen T; Midtvedt Ø; Andreassen AK; Lund-Johansen F; Distler O; Belperio J; Hoffmann-Vold AM
    Front Immunol; 2022; 13():991743. PubMed ID: 36211384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis.
    van Bon L; Affandi AJ; Broen J; Christmann RB; Marijnissen RJ; Stawski L; Farina GA; Stifano G; Mathes AL; Cossu M; York M; Collins C; Wenink M; Huijbens R; Hesselstrand R; Saxne T; DiMarzio M; Wuttge D; Agarwal SK; Reveille JD; Assassi S; Mayes M; Deng Y; Drenth JP; de Graaf J; den Heijer M; Kallenberg CG; Bijl M; Loof A; van den Berg WB; Joosten LA; Smith V; de Keyser F; Scorza R; Lunardi C; van Riel PL; Vonk M; van Heerde W; Meller S; Homey B; Beretta L; Roest M; Trojanowska M; Lafyatis R; Radstake TR
    N Engl J Med; 2014 Jan; 370(5):433-43. PubMed ID: 24350901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An update on biomarker discovery and use in systemic sclerosis.
    Matsushita T; Takehara K
    Expert Rev Mol Diagn; 2017 Sep; 17(9):823-833. PubMed ID: 28730919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CXCL4 in undifferentiated connective tissue disease at risk for systemic sclerosis (SSc) (previously referred to as very early SSc).
    Valentini G; Riccardi A; Vettori S; Irace R; Iudici M; Tolone S; Docimo L; Bocchino M; Sanduzzi A; Cozzolino D
    Clin Exp Med; 2017 Aug; 17(3):411-414. PubMed ID: 27650429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CXCL4 triggers monocytes and macrophages to produce PDGF-BB, culminating in fibroblast activation: Implications for systemic sclerosis.
    van der Kroef M; Carvalheiro T; Rossato M; de Wit F; Cossu M; Chouri E; Wichers CGK; Bekker CPJ; Beretta L; Vazirpanah N; Trombetta E; Radstake TRDJ; Angiolilli C
    J Autoimmun; 2020 Jul; 111():102444. PubMed ID: 32284212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Mechanisms Behind the Role of Plasmacytoid Dendritic Cells in Systemic Sclerosis.
    Silva IS; Ferreira BH; Almeida CR
    Biology (Basel); 2023 Feb; 12(2):. PubMed ID: 36829561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Autoimmunity to Peptides of Collagen V α1 Chain as Newly Biomarkers of Early Stage of Systemic Sclerosis.
    Velosa APP; Brito L; de Jesus Queiroz ZA; Carrasco S; Tomaz de Miranda J; Farhat C; Goldenstein-Schainberg C; Parra ER; de Andrade DCO; Silva PL; Capelozzi VL; Teodoro WR
    Front Immunol; 2020; 11():604602. PubMed ID: 33643291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of serum CCL20 levels with pulmonary vascular involvement and primary biliary cholangitis in patients with systemic sclerosis.
    Ikawa T; Miyagawa T; Fukui Y; Minatsuki S; Maki H; Inaba T; Hatano M; Toyama S; Omatsu J; Awaji K; Norimatsu Y; Watanabe Y; Yoshizaki A; Sato S; Asano Y
    Int J Rheum Dis; 2021 May; 24(5):711-718. PubMed ID: 33750014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and serological associations with anti-RNA polymerase antibodies in systemic sclerosis.
    Harvey GR; Butts S; Rands AL; Patel Y; McHugh NJ
    Clin Exp Immunol; 1999 Aug; 117(2):395-402. PubMed ID: 10444276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subspecificities of anticentromeric protein A antibodies identify systemic sclerosis patients at higher risk of pulmonary vascular disease.
    Perosa F; Favoino E; Favia IE; Vettori S; Prete M; Corrado A; Cantatore FP; Valentini G
    Medicine (Baltimore); 2016 Jun; 95(25):e3931. PubMed ID: 27336883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.